Cancer BiologybioRxivPreprint
A novel pan class-I glucose transporter inhibitor DRB18 exhibits synergistic effects in vitro and in vivo with paclitaxel against human non-small cell lung cancer
Pratik Shriwas, Lindsey M. Bachmann, Ryan A. Ward…·Xiaozhuo Chen
This study shows that DRB18, a pan-class I GLUT inhibitor, synergizes with paclitaxel to reduce NSCLC cell proliferation in vitro and tumor growth in vivo.
1 citation